hypertension
Conditions
Interventions
Eplerenone (Trade name: Selara, Pfizer Inc.)50mg once a day
Trichlormethiazide (Trade name: Fluitran, Shionogi &
Co., Ltd.)1mg once a day
Sponsors
Departmenet of Internal Medicine Division of Cardio-Vascular Medicine and Department of Community Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Out Patients 2.Patients who are with BMI >=25kg/m2 and SBP>=140mmHg and/or DBP>= 90mmHg at consalting room
Exclusion criteria
Exclusion criteria: 1.Patients on eplerenone or spironolactone during 3 months prior to enrollment 2.Patients on diuretics including trichlormethiazide or combination drugs during 3 months prior to enrollment 3. Patients who experienced myocardial infarction or stroke during 30 days prior to enrollment 4.Patients who had cardiac surgery or PCI during 30 days prior to enrollment 5. Patients with serum potassium >= 5.0 mEq/L 6.Patients with severe liver dysfunction 7.Patients with severe renal dysfunction 8.Patients with grade III hypertension (SBP >=180mmHg and/or DBP >=110mmHg) 9.Patients diagnosed as having secondary hypertension 10.Patients with hypersensitivity with eplerenone or sulfonamide derivative 11.Patients who are contraindicated for use of eplerenone or trichlormethiazide 12.Patients who are on medications contraindicated for use with eplerenone or trichlormethiazide 13.Women who are either pregnant, lactating or of childbearing potential 14.Patients who are considered not appropriate to enroll into this trial under the judgment of the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in office SBP/DBP after 24 weeks Change from baseline in insulin sensitivity (homeostasis model assessment insulin resistance (HOMA-IR)) after 24 weeks Change from baseline in HbA1c after 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes from baseline in hsCRP, eGFR, and adiponectin | — |
Countries
Japan
Contacts
Public ContactHisashi Adachi
Kurume University School of Medicine Departmenet of Internal Medicine Division of Cardio-Vascular Medicine and Department of Community Me
Outcome results
None listed